News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

IMPEL NEUROPHARMA ANNOUNCES FDA SUBMISSION OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

~The INP104 New Drug Application is Supported by Results from the Phase 3 STOP 301 Study~ ~Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper…

READ MORE

IMPEL NEUROPHARMA PRESENTS DATA FROM PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE AT 2020 MIGRAINE TRUST VIRTUAL SYMPOSIUM

66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES PUBLICATION OF POSITIVE RESULTS OF SNAP 101 STUDY FOR INP105 FOR THE TREATMENT OF ACUTE AGITATION IN THE JOURNAL OF CLINICAL PSYCHIATRY

Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting INP105 is a Powder Formulation of Olanzapine, the Gold Standard Treatment for Acute…

READ MORE

IMPEL NEUROPHARMA PRESENTS DATA FROM INP104 CLINICAL PROGRAM IN ACUTE MIGRAINE AT THE 2020 AMERICAN HEADACHE SOCIETY (AHS) VIRTUAL ANNUAL SCIENTIFIC MEETING

Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company’s Pivotal Phase 3 Study of INP104 for…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES PRIMARY OBJECTIVES MET IN PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE

Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes…

READ MORE

Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams’ Role Expanded To Chairman and CEO

SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of…

READ MORE

Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs – Migraine Franchise

January 16, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Sheena K.…

READ MORE

Impel NeuroPharma Announces Appointment of Adrian Adams as Chairman of The Board of Directors

January 9, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced the appointment of Adrian Adams…

READ MORE